

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

**VOLUNTARY ANNOUNCEMENT
RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY
CHINESE MEDICINE**

This announcement is made by Tong Ren Tang Technologies Co. Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company’s subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”) received the Certificate of Registration of Proprietary Chinese Medicine (《中成藥註冊證明書》) issued by the Chinese Medicine Council of Hong Kong (the “**Certificate**”), allowing “Sanzi Yangqin Keli【Tong Ren Tang】” (三子養親顆粒【同仁堂】) to be sold in the Hong Kong Special Administrative Region of the People’s Republic of China (“**Hong Kong**”). The relevant details are as follows:

I. Basic Information of the Medicine

Name of the medicine: Sanzi Yangqin Keli 【Tong Ren Tang】 (三子養親顆粒【同仁堂】)

Registrant and address: Beijing Tong Ren Tang Chinese Medicine Company Limited at 3 Dai King Street, Tai Po Industrial Estate, New Territories, Hong Kong

Registration number: HKC-18820

Certificate validity period: Until 25 August 2031

II. Other Related Information of the Medicine

The function and main indications of the “Sanzi Yangqin Keli【Tong Ren Tang】” are to warm the lung and resolve phlegm, direct qi downward and promote digestion. It is used for qi stagnation pattern due to phlegm congestion, manifested as cough and panting, excessive phlegm and chest stuffiness, reduced food intake and hard to digest, with the white and greasy tongue coating and the slippery pulse. As at the date of this announcement, the Group has cumulatively invested approximately HK\$800,000 (unaudited) in the research and development of “Sanzi Yangqin Keli【Tong Ren Tang】”. This product has not yet been launched for sales in market.

III. Impact on the Company and Risk Warning

Upon obtaining the Certificate, “Sanzi Yangqin Keli【Tong Ren Tang】” produced by Tong Ren Tang Chinese Medicine can be sold in Hong Kong, which is conducive to expanding the product lines of the Group and beneficial to the Group’s market expansion. The obtaining of the Certificate will not have any material impact on the production, operation and performance of the Group for the time being. The sales of pharmaceutical products can be influenced by factors such as change in the policy environment, exchange rate fluctuations and market competition in the Hong Kong region.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Tong Ren Tang Technologies Co. Ltd.

Zhang Yi

Chairman of the Board

Beijing, the PRC

28 August 2026

As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza and Mr. Zhan Yuan Jing and Mr. Siu, Paul Yu Hey as independent non-executive Directors, Mr. Zhu Dong Sheng as employee Director.